SurgicEye® Announces Its Cooperation with RMD Instruments for the Future Development of 3D Radio-Guided Surgery
Intraoperative 3-D Imaging for Radio-guidance of Tumors and Sentinel Lymph Nodes.
Munich, Germany, October 16, 2011 --(PR.com)-- SurgicEye®, the leading provider of intraoperative soft tissue imaging and navigation solutions, and RMD, a leading provider of gamma detection devices announced their cooperation of common activities for 3D radio-guided surgery.
RMD, a pioneer and innovator in gamma detection devices, designs, manufactures and sells the Navigator GPS system. The Navigator System is used intra-operatively for staging cancer, primarily in breast, melanoma and lung cancer.
SurgicEye's declipseSPECT® / CSS300 provides intra-operative 3-D image visualization and navigation of RMD’s Navigator GPS system during radio-guided surgery. The solution combines gamma probes with imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases, and sentinel lymph nodes in a minimally invasive approach. This intra-operative imaging technology contributes to quality assurance and provides evidence for complete sentinel lymph node (SLN) and tumor resection during the surgery.
"The declipseSPECT technology and its intraoperative use for navigated sentinel lymph node dissection will enable safer surgeries, and less invasive procedures. This can ensure a high quality outcome for every individual patient," said Prof. Dr. Marion Kiechle, Director of the Women's Hospital at Klinikum rechts der Isar in Munich, Germany. Prof. Kiechle and her leading breast surgeons, Dr. Stefan Paepke and Dr. Andreas Schnelzer, are the primary European investigators of declipseSPECT in breast cancer applications.
Gordon Lewis, General Manager of RMD Instruments Corp. said, "declipseSPECT, when combined with the GPS Navigator, makes the localization and resection of radioactive structures extremely intuitive, reliable and minimally invasive." He notes that the SurgicEye technology fits within RMD's strategic vision of providing the most clinically advanced solutions for patient-tailored care.
The founder and CEO of SurgicEye, Dr. Joerg Traub, is convinced that, "The cooperation between the two companies will provide high-quality products and services to the medical device market. The Navigator GPS of RMD is a high quality and reliable gamma probe system for the detection of radio-pharmaceuticals, a fundamental component to providing confident image information for surgical guidance."
The integrated solution has CE certification and will be introduced to the EU market during the Annual Meeting of the European Association of Nuclear Medicine Society (EANM) in Birmingham, UK October 16-18, 2011. Both, SurgicEye and RMD will exhibit the integrated solution at booth 21 during the EANM.
About SurgicEye
SurgicEye offers solutions for intraoperative 3-D imaging and instrument navigation. The recent product declipseSPECT of SurgicEye implements the so-called freehand SPECT technology for detection, localization and guided biopsy of sentinel lymph nodes in breast cancer, melanoma and head & neck malignancies. Clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgery. It enables surgical procedures to be more sensitive, more reliable and less invasive. For more information on SurgicEye, please visit www.surgiceye.com.
###
RMD, a pioneer and innovator in gamma detection devices, designs, manufactures and sells the Navigator GPS system. The Navigator System is used intra-operatively for staging cancer, primarily in breast, melanoma and lung cancer.
SurgicEye's declipseSPECT® / CSS300 provides intra-operative 3-D image visualization and navigation of RMD’s Navigator GPS system during radio-guided surgery. The solution combines gamma probes with imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases, and sentinel lymph nodes in a minimally invasive approach. This intra-operative imaging technology contributes to quality assurance and provides evidence for complete sentinel lymph node (SLN) and tumor resection during the surgery.
"The declipseSPECT technology and its intraoperative use for navigated sentinel lymph node dissection will enable safer surgeries, and less invasive procedures. This can ensure a high quality outcome for every individual patient," said Prof. Dr. Marion Kiechle, Director of the Women's Hospital at Klinikum rechts der Isar in Munich, Germany. Prof. Kiechle and her leading breast surgeons, Dr. Stefan Paepke and Dr. Andreas Schnelzer, are the primary European investigators of declipseSPECT in breast cancer applications.
Gordon Lewis, General Manager of RMD Instruments Corp. said, "declipseSPECT, when combined with the GPS Navigator, makes the localization and resection of radioactive structures extremely intuitive, reliable and minimally invasive." He notes that the SurgicEye technology fits within RMD's strategic vision of providing the most clinically advanced solutions for patient-tailored care.
The founder and CEO of SurgicEye, Dr. Joerg Traub, is convinced that, "The cooperation between the two companies will provide high-quality products and services to the medical device market. The Navigator GPS of RMD is a high quality and reliable gamma probe system for the detection of radio-pharmaceuticals, a fundamental component to providing confident image information for surgical guidance."
The integrated solution has CE certification and will be introduced to the EU market during the Annual Meeting of the European Association of Nuclear Medicine Society (EANM) in Birmingham, UK October 16-18, 2011. Both, SurgicEye and RMD will exhibit the integrated solution at booth 21 during the EANM.
About SurgicEye
SurgicEye offers solutions for intraoperative 3-D imaging and instrument navigation. The recent product declipseSPECT of SurgicEye implements the so-called freehand SPECT technology for detection, localization and guided biopsy of sentinel lymph nodes in breast cancer, melanoma and head & neck malignancies. Clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgery. It enables surgical procedures to be more sensitive, more reliable and less invasive. For more information on SurgicEye, please visit www.surgiceye.com.
###
Contact
SurgicEye GmbH
Claudia Ramirez-Wiesner
+49 8954 9989001
www.surgiceye.com
Claudia Ramirez-Wiesner
+49 8954 9989001
www.surgiceye.com
Contact
Categories